DiaMedica Therapeutics | 8-K: FY2025 Q3 Revenue: USD 0

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -0.17, missing the estimate of USD -0.16.

EBIT: As of FY2025 Q3, the actual value is USD -9.452 M.

Cash Position

Cash and short-term investments were $55.3 million as of September 30, 2025, compared to $44.1 million as of December 31, 2024. The increase is attributed to net proceeds from a July private placement.

Cash Flows

Net cash used in operating activities for the nine months ended September 30, 2025, was - $21.3 million, compared to - $15.6 million for the same period in 2024, primarily due to increased net loss.

Research and Development (R&D)

R&D expenses were $6.4 million and $17.9 million for the three and nine months ended September 30, 2025, respectively, up from $5.0 million and $12.6 million for the same periods in the prior year, driven by the progress of the ReMEDy2 clinical trial and expansion of the clinical team.

General and Administrative (G&A)

G&A expenses were $2.6 million and $7.3 million for the three and nine months ended September 30, 2025, respectively, up from $1.9 million and $5.7 million for the same periods in 2024, due to increased non-cash share-based compensation and personnel costs.

Net Loss

Net losses were - $8.6 million and - $24.0 million for the three and nine months ended September 30, 2025, respectively, up from - $6.3 million and - $16.5 million for the same periods in 2024.

Outlook / Guidance

DiaMedica anticipates its current cash and short-term investments will fund planned clinical studies and support corporate operations into the second half of 2027. The company expects continued enrollment in the ReMEDy2 trial, nearing 50% of the target of 200 participants for interim analysis expected in the second half of 2026. The company plans to provide updates regarding the FDA meeting once final minutes are received.